Researchers at the 2024 ASCO Annual Meeting evaluated the performance of myelofibrosis prognostic models at an inner-city tertiary care center, characterized by diverse patient demographics, delayed disease presentation, and limited health – care access. Josette Mary Kamel and colleagues conducted a retrospective analysis of 88 patients (mean age, 66; median survival, 7.7 years) from 2000 to 2023, using clinical and genetic data to calculate scores with the Dynamic Inter – national Prognostic Scoring System (DIPSS), DIPSS Plus, Mutation-Enhanced International Prognostic Scoring System 70 (MIPSS70), MIPSS70v2, and Genetically Inspired Prognostic Scoring System (GIPSS). Univariate analysis showed significant associations between OS and DIPSS (n=88; HR, 1.77; 95% CI, 1.22-2.41; P=0.0001), DIPSS plus (n=83; HR, 1.54; 95% CI, 1.15-2.07; P=0.0033), MIPSS70v2 (n=68; HR, 2.06; 95% CI, 1.23-3.61; P=0.0088), and GIPSS (n=69; HR, 2.73; 95% CI, 1.24-3.78; P=0.0063). DIPSS and GIPSS remained significant upon multivariate adjustment (P=0.009 and P=0.043, respectively). Predictive accuracy was highest with combined DIPSS and GIPSS analysis (C-index=0.773). The study concludes that these models are valid for inner-city populations, with combined clinical and genetic models offering superior predictive value.